Transfusion of hydroxyethylated amylopectin-protected frozen blood in man. I. Plasma clearance and renal excretion of the cryoprotectant.
In man following the autologous transfusion of blood previously frozen with 14% low molecular weight-hydroxyethylated amylopectin (cryo-HES), the clearance of this material from the intravascular space was compound, and appeared to consist of exponential components. The overall half-life -- however, was 10.6 +/- 3.0 (SD) h. Approximately 17% of the total infused cryo-HES was excreted in the urine 1 h postinjection, and 40% by 72 h. The erythrocyte sedimentation rate (ESR) was not affected by the presence of this substance in the bloodstream of the recipient. The results indicate that cryo-HES is removed rapidly following the transfusion of blood previously frozen with this material.
D000328:Adult; D000687:Amylopectin / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology / Q000652:urine; D001803:Blood Transfusion; D003451:Cryoprotective Agents / Q000378:metabolism; D005615:Freezing; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000097:blood / Q000494:pharmacology* / Q000652:urine; D007668:Kidney / Q000378:metabolism*; D008297:Male; D013213:Starch / Q000031:analogs & derivatives*
D003451:Cryoprotective Agents; D006895:Hydroxyethyl Starch Derivatives; D013213:Starch; D000687:Amylopectin